Eloxx Pharmaceuticals, Inc. (ELOX) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule product candidates to treat genetic diseases caused by nonsense mutations. The company's lead candidate, exaluren, is in development for rare kidney diseases (Alport Syndrome and ADPKD). A second candidate, ZKN-013, has been exclusively licensed to Almirall for rare skin diseases. The company is currently listed on the OTC Expert Market following a suspension from the Nasdaq Capital Market in October 2023.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3.75) million | $(1.71) million |
| Operating Expenses | $3.80 million | $1.22 million |
| Cash and Cash Equivalents | $6.36 million | $0.45 million |
| Accumulated Deficit | $(304.33) million | $(296.29) million |
| Outstanding Debt | $0 | $1.0 million (current portion) |
| Net Cash Used in Operating Activities | $(5.45) million | $1.20 million (provided) |
| Net Cash Provided by Financing Activities | $7.03 million | $(0.87) million (used) |
Material Changes vs. Prior Period
- Expense Increase: Total operating expenses increased by 211% to $3.80 million, driven by a 225% rise in R&D expenses (to $1.66 million) and a 200% rise in G&A expenses (to $2.14 million). R&D increases were due to clinical trial costs and preclinical activities; G&A increases were due to professional fees and audit costs.
- Debt Elimination: The company extinguished all outstanding debt obligations ($1.0 million) in February 2026 by exchanging them for pre-funded warrants. This resulted in a $0.06 million gain on extinguishment of accrued interest.
- Financing Activity: The company raised approximately $7.0 million in net proceeds through the issuance of pre-funded warrants to Coastlands Capital Partners and Domicilium during the quarter.
- Cash Position: Cash and cash equivalents increased significantly from $0.45 million in Q1 2025 to $6.36 million in Q1 2026, primarily due to the financing activities mentioned above.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management states that cash on hand ($6.4 million) is not sufficient to fund operations for the next 12 months. The filing explicitly states that these conditions raise "substantial doubt about the Company's ability to continue as a going concern."
- Clinical Pipeline: The company plans to initiate a Phase 2b clinical trial for exaluren in Alport Syndrome in the first half of 2026, with topline data expected by mid-2027. A Phase 2 trial for ADPKD is planned for 2027.
- Capital Needs: The company will need to raise additional capital through debt or equity financing to continue operations. Failure to do so may force the company to delay or terminate product development.
- Internal Controls: The company identified a material weakness in internal controls over financial reporting related to inconsistent execution of financial close and reconciliation processes. This weakness had not been remediated as of March 31, 2026.
- Listing Status: The company intends to seek an uplisting to the Nasdaq Capital Market but notes there are no assurances of success.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline and probability of securing the additional capital required to fund operations beyond the next 12 months.
- Internal Control Remediation: Monitor progress on remediation of the material weakness in financial reporting controls.
- Dilution Risk: Review the terms of the pre-funded warrants issued in Q1 2026, which significantly increased the number of potential shares outstanding (weighted average shares used for EPS calculation jumped to ~48.2 million).
- Clinical Milestones: Track the initiation of the Phase 2b trial for exaluren in H1 2026 as a critical value inflection point.
- Debt Obligations: Confirm that no new debt has been incurred and that the royalty/revenue sharing agreements with Domicilium do not create immediate cash flow burdens.